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Translating the genetic code from nucleotide information to
amino acid sequence is the function of aminoacyl-tRNA syn-
thetases (ARSs). By specifically recognizing tRNAs and cat-
alyzing the incorporation of their cognate amino acids to the 3′
terminal ribose of the tRNA, ARSs ensure that each amino acid
incorporated by the ribosome into a growing polypeptide
matches the information contained in the codon-anticodon
pairing.
The tRNA aminoacylation reaction by ARSs proceeds in two
enzymatic steps that take place within a single active-site do-
main of the enzymes:
1) ARS + aa + ATP → ARS-aaAMP + Ppi
2) ARS-aaAMP + tRNA → ARS + AMP + aa-tRNA
In the first part of the reaction, the enzymes activate the
amino acid with ATP to form aminoacyl-adenylate, with release
of pyrophosphate. Next, the amino acid is transferred, via the
formation of an ester bond, to a hydroxyl group of the ribose of
the terminal adenosine at the 3′-end of the tRNA, thus generat-
ing aminoacyl-tRNA and AMP. Each amino acid is recognized
by its own specific ARS, which is universally distributed [4].
The typical tRNA is made up of 76 nucleotides that fold into
a cloverleaf structure consisting of four stems and three loops.
The 3′-end terminates in the universal CCA3′-OH with the termi-
nal A3′-OH being the amino acid attachment site (Fig. 1). The
seven base pairs adjacent to the amino acid acceptor site con-
stitute the acceptor stem. The anticodon triplet is in a loop at
the opposite end of the cloverleaf.
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Resum
Les aminoacil-tRNA sintetases (ARSs) són els enzims que tra-
dueixen el codi genètic unint aminoàcids a l’RNA de trans-
ferència (ARNt) corresponent. Els tRNA aminoacilats poden
ser utilitzats aleshores pel ribosoma per traduir RNA missat-
gers (mRNA). El rol essencial de les ARS es va establir en la
dècada dels seixanta, durant l’era d’or de la biologia molecu-
lar, que va dur al descobriment del codi genètic. El paper
canònic d’aquests enzims es troba actualment descrit en tots
els llibres de text. Tot i això, l’interès per la funció de les ARS
continua creixent extraordinàriament, a causa de les noves i
inesperades funcions descobertes per a aquests enzims, per
a l’ARNt i per a l’ARN en general. En aquest article descriurem
els darrers progressos en l’estudi de les aminoacil-tRNA sinte-
tases, resumirem els coneixements actuals sobre l’evolució de
les ARS, introduirem els lectors en diverses facetes de la bio-
logia cel·lular en què s’ha comprovat que les ARS tenen un
paper important i discutirem les aplicacions derivades d’a-
quests estudis.
Abstract
Aminoacyl-tRNA synthetases (ARSs) are enzymes that trans-
late the genetic code by adding amino acids to their cognate
transfer RNAs (tRNA). Aminoacylated tRNAs can then be used
by the ribosome to decode mRNA. The essential role of ARSs
was established in the 1960s, during the golden era of molecu-
lar biology that led to the discovery of the genetic code. The
canonical role of these enzymes is now described in all text-
books. Remarkably, however, interest in ARS function contin-
ues to grow as new and unexpected functions are discovered
for these enzymes, for tRNA, and for RNA in general. This arti-
cle describes current progress in the field of ARS research,
summarizes current thinking about the evolution of ARSs, in-
troduces the readers to the many facets of cellular biology in
which ARSs play an important role, and discusses the biotech-
nological applications derived from these studies.
Paraules clau: Aminoacil-tRNA sintetases, tRNA,
síntesi proteica, antibiòtics, evolució
Keywords: Aminoacyl-tRNA synthetases, tRNA,
protein synthesis, antibiotics, evolution
* Author for correspondence: Lluís Ribas de Pouplana, Institut de Re-
cerca Biomèdica, Laboratori de la Traducció Genètica, Parc Científic de
Barcelona. C/ Josep Samitier 1-5. 08028 Barcelona, Catalonia, EU.
Tel 34 934034867. Fax: 34 934034870. Email: lluisribas@pcb.ub.es
117-186 Contributios 3.2  4/5/07  08:38  Página 149
150 T. Bori-Sanz, T. Guitart and L. Ribas
Recognition of tRNAs by ARSs depends mostly on molecular
interactions with the acceptor stem and the anticodon loop of the
tRNA. The active-site domains of the enzymes bind the acceptor
arm of the tRNA molecule, where the amino acid is attached.
Recognition of the anticodon is achieved through domains at-
tached to the active sites. These domains are not universally
conserved, and vary from enzyme to enzyme and from species
to species [5, 6]. The ARSs are evenly divided into two classes of
ten enzymes each [7, 8]. All enzymes within a class appear to
have evolved from a single-domain ATP-binding protein. Inser-
tions into and variations on this domain established a framework
for binding the tRNA acceptor stem. Over the course of evolution
additional domains were added to this core structure [9].
Evolution of aminoacyl-tRNA synthetases
At the biochemical level, the genetic code is established by the
action of tRNA synthetases. For that reason, ARSs are at the
center of research on, and theories of, the origin of life [9-12],
and their evolution is thought to be closely connected with the
early development of the genetic code.
Despite the close functional relationship between the
aminoacylation activities of tRNA synthetases and the genetic
code, attempts to relate the evolution of these enzymes to the
development of the code have been inconclusive [12]. How-
ever, recent work on the structures of synthetase–tRNA com-
plexes and on the evolutionary relationships within this family of
enzymes has provided a framework within which specific fea-
tures of the code and the synthetases can be examined. In par-
ticular, synthetases may have developed as pairs of tRNA-
binding proteins that mirrored the increase in complexity of the
tRNA molecules [8]. Thus, the extant families of synthetases
are a product of genetic code development, and their structur-
al relationships could reflect the nature of intermediate steps in
the establishment of codon–amino acid interactions.
The 20 ARSs comprise two distinct families of enzymes (Fig.
2) [7, 8, 13], each of which originated from an ancient, distinct
Figure 1. Secondary (left) and tertiary (right) structure of tRNA. The secondary-structure sequence corresponds to human mitochondrial tRNALeu.
The three-dimensional structure corresponds to Saccharomyces cerevisiae tRNAAsp. The phosphate backbone is shown as a gray tube, and the
bases as black discs.
Figure 2. Classification of aminoacyl-tRNA synthetases according to
their three-dimensional structure.
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single-domain protein [9]. This domain contains the active site
for adenylate synthesis (condensation of an amino acid with
ATP to give the aminoacyl adenylate) and for attachment of the
activated amino acid to the 3′-end of tRNA. However, the
structures of the ancestral domains for the two families are un-
related and, in spite of extensive research, no evidence exists
for a common ancestor.
The two families of enzymes are known as class I and class
II, and, with one exception, the class to which a synthetase is
assigned is constant throughout evolution [13-18]. The 11
class I enzymes are characterized by an active site domain that
has a Rossmann nucleotide-binding fold composed of alter-
nating β-strands and α-helices [19, 20]. From statistical analy-
ses of the several hundred sequences of class I enzymes avail-
able from prokaryotes, archaea, and eukaryotes, the
synthetases can be further divided into three subgroups (Fig. 2)
[18]. As expected, these subclass groupings are also consis-
tent with structural comparisons between the enzymes within
the class.
The three subclasses are designated Ia, Ib, and Ic. Each
subclass is thought to have its own common ancestor that
arose after the progenitor of the entire class. The enzymes in
each subclass show a tendency to recognize amino acids
that are chemically related. For example, members of sub-
class Ia recognize hydrophobic amino acids, such as the
branched aliphatics (Ile, Leu, and Val), and amino acids with
sulfur-containing residues (Met and Cys). Argininyl-tRNA syn-
thetase is also assigned to this subgroup. Subclass Ib en-
zymes recognize charged amino acids (Glu and Lys) and the
derivative Gln. Subclass Ic enzymes recognize the aromatics
Tyr and Trp.
By contrast, the active sites of the ten class II enzymes are
made up of a seven-stranded β-sheet with flanking α-helices
[21, 22]. Statistical analyses of sequences of class II enzymes
show that, similar to their class I counterparts, they can be di-
vided into three subclasses (Fig. 2). Subclass IIa enzymes rec-
ognize groupings of chemically similar side-chains, such as
aliphatics (Ala and Pro) and polar (Ser, Thr, Pro, His) side
chains as well as Gly. The charged side-chains Asp and Lys,
and the derivative Asn are recognized by enzymes in subclass
IIb, whereas subclass IIc synthetase recognizes the one re-
maining aromatic, Phe.
Thus, the two classes have a certain ‘symmetry’, with en-
zymes for chemically (or sterically) similar amino acids placed
across from each other in subclasses with similar numbers of
enzymes. This symmetry between the two classes is also seen
in other ways. For example, members of class I approach the
acceptor stem of tRNA from the minor-groove side, whereas
those of class II approach from the major-groove side [23].
Also, class I enzymes attach the amino acid to the 2′-hydroxyl
whereas those of class II charge the 3′-hydroxyl [24, 25].
Based on all of these considerations, the division of the 20 en-
zymes into two classes of almost identical size, with specific
and matching subclasses, does not seem coincidental. This
organization is consistent with the development of paired syn-
thetases, ultimately giving rise to two classes with equal num-
bers of enzymes [8].
An ancestral complex of one tRNA and two ARSs
Since the enzymes in the two classes bind to opposite sides of
the tRNA acceptor stem, the possibility that a single acceptor
stem can simultaneously bind a synthetase from each class
was investigated by molecular modeling. Indeed, subclass-
specific pairings can be made without any steric clashes (Fig.
3) [8]. However, not all combinations of class I and class II ac-
tive-site domains on the acceptor stem can be paired together.
Several combinations result in large steric clashes between the
core regions of the proteins. Moreover, although the details of
how each synthetase binds its cognate tRNA are idiosyncratic,
with both translational and rotational changes occurring in the
precise fit on the acceptor stem, these changes are coordinat-
ed so that the result is subclass-specific pairings [8].
Most striking is the way that tyrosyl-tRNA synthetase (TyrRS)
and phenyl-tRNA synthetase (PheRS) are mutually accommo-
dating. The binding of each of these enzymes involves large ro-
tational and translational changes relative to other members in
its respective class. And yet, these large changes are exactly
compensated so that the active site domains of both enzymes
can still bind simultaneously onto a tRNA (Fig. 3).
Thus, the remarkable symmetry between the two extant
classes of synthetases can be viewed as a consequence of the
interaction of specific synthetase pairs in complex with tRNA.
These pairs might have evolved to cover and protect the ac-
ceptor stem in environments (such as high temperature) where
the structure of RNA was especially vulnerable [8]. At this
stage, the charging reactions might have been catalyzed by
other molecules, possibly ribozymes, that were later replaced
by the synthetases [26–29].
A correlation between ARS pairs and the structure of the
genetic code
The structural pairings of tRNA synthetases link specific class I
and II subclasses and suggest that an interaction existed be-
tween the two ancestral proteins of the paired subclasses [30].
The evolution of extant enzymes from these ancestral pairs can
explain the similarities found among the two synthetase clas-
ses. This physical link between subclass ancestors has impor-
tant implications with regard to the ancestral nature of the
translation machinery and the genetic code.
This model implies the existence of a primitive genetic code
that translated proteins using a reduced number of tRNAs or
mini-helix-like structures that might have been tRNA precur-
sors. The association of ancestral synthetases in pairs sug-
gests a smaller number of total tRNA entities and a reduced
number of amino acids. If synthetases had simply replaced a
set of 20 pre-existing aminoacylating ribozymes that recog-
nized a set of 20 different tRNAs, there would be no reason to
expect the symmetrical nature of the two extant synthetase
classes.
The primitive genetic code was probably capable of encod-
ing single-domain proteins with the complexity of synthetase
active sites that specifically recognized RNA structures. This
translation machinery must have had a degree of coding ac-
curacy. Ambiguous codons might have been used for families
of related side-chains, and the actual distribution of incorpo-
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rated side-chains might have depended on the relative con-
centrations of these similar amino acids. Indeed, recent ex-
periments demonstrated that even contemporary organisms,
such as Escherichia coli, can tolerate high levels of coding
ambiguity [31] .
Expansion and establishment of the final genetic code were
probably achieved through duplication and mutation of the
genes encoding tRNAs [32–34]. Equivalent duplications and
changes of the associated pairs of synthetases would have fol-
lowed the expansion of the tRNA set. This implies that a rela-
tionship should exist between extant codons for amino acids
that are recognized by synthetases whose ancestors were
paired.
As shown in Fig. 4, specific patterns of codon distribution
can be seen when these are organized according to the pro-
posed pairings of synthetase subclasses. This depiction shows
that each of the three pairings of subclasses is related to the
code in a way that is peculiar to the specific pairing. Thus, the
codon assignments associated with 16 amino acids appear to
have been constrained by selective pressures that operated
through the subclass pairings of the associated synthetases.
As expected, these constraints are pair-specific. Moreover,
such constraints would only be expected for code assign-
ments achieved during the period in which aminoacyl-tRNA
synthetase pairs existed. Early and late amino acid codon as-
signments that took place before the advent of synthetase
pairing, or after the separation of these complexes, would not
necessarily follow these correlations.
In a putative RNA world, aminoacylation is thought to have
originated with ribozymes that catalyzed attachment of specific
amino acids to tRNA precursors [26-29]. Subsequently, ri-
bozymes would be replaced with ribozyme-like RNA–peptide
complexes and, eventually, with ribonucleoproteins (RNPs).
RNPs with aminoacylation activity could be the precursors of
modern tRNA synthetases.
Coded peptide synthesis could have emerged during this
evolutionary process. With a simple code, a limited set of
amino acids would initially have been used to generate proteins
[32]. Early synthetases could have originated as crude proteins
that covered and protected the tRNA acceptor stem and par-
ticipated either directly or indirectly (in conjunction with a ri-
bozyme-like catalyst) in aminoacylation. At this point, the
emerging class I and class II tRNA synthetases might have
been under strong selective pressure to develop amino acid or
ATP affinities to increase the efficiency of the aminoacylation
reaction. This resulted in the formation of the ATP-binding
pockets that are conserved among all members within a given
ARS class, irrespective of their subclass. During this phase of
evolution, the development of synthetases and the emerging
tRNA structure were undoubtedly coupled and, ultimately, one
of the two synthetase domains replaced the aminoacylation
activity of the pre-existing ribozyme.
Figure 3. Pairs of sterically compatible aminoacyl-tRNA synthetases (ARSs) active sites around a single tRNA.
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Duplication and divergence of this RNP complex generated
at least three different species: the ancestors of the three sub-
class-pairings suggested by extant synthetase structures (Fig.
3) [8]. As the genetic code became more complex, the assign-
ment of codons to new amino acids required the duplication
and divergence of existing tRNAs and their associated syn-
thetase domains. Specific recognition of the newly incorporat-
ed amino acid was achieved by evolving an active site with new
specificity in the other member of the synthetase pair (Fig. 4).
This established the symmetry in side-chain specificity seen
among the paired synthetase subclasses (Fig. 2) [30].
From this point onwards, each complex evolved to optimize
its amino acid and tRNA specificity. Better recognition of the
tRNA molecule, particularly through new interactions with the
anticodon, was achieved through the incorporation of idiosyn-
cratic domains into each individual complex, and the original
active site pairs split apart as a consequence of steric clashes
or other factors [30].
New functions of aminoacyl-tRNA synthetases
ARSs have traditionally been considered housekeeping en-
zymes, solely dedicated to the aminoacylation of their specific
tRNAs. However, as our understanding of biological processes
increases and the amount of sequence information grows, it
becomes increasingly evident that these enzymes are involved
in many other biological processes. In bacteria and yeast,
these new functions tend to include transcription or translation
regulation, whereas in higher eukaryotes ARSs seem to have
incorporated sophisticated roles in cell cycle control and sig-
naling that are unrelated to the protein synthesis apparatus.
Gene transcription and translation control by ARSs
In bacteria, ARSs are involved in the regulation of gene expres-
sion. This phenomena was first described in Bacillus subtilis
[35], but the regulation mechanism controlled by Escherichia
coli threonyl-tRNA synthetase (ThrRS) is the best-documented
and understood [36].
E. coli ThrRS negatively regulates the expression of its own
gene (thrS) at the translational level [37]. The enzyme binds to a
site, the operator, positioned in the leader region of its own
mRNA and inhibits initiation of translation by competing with
the 30S ribosomal subunit [38]. The operator is composed of
four structural domains. Domain 1 is single-stranded and car-
ries the Shine-Dalgarno (SD) sequence and the initiation
codon. Domain 3 is also single-stranded and links two
stem–loop structures (domains 2 and 4) that carry sequence
analogies with the anticodon loop of tRNAThr (Fig. 5).
The binding sites for ThrRS and the ribosome are overlap-
ping in the leader RNA [39]. While the ribosome recognizes do-
main 1 and domain 3, ThrRS binds specifically and symmetri-
cally to the two stem-loops in domains 2 and 4 in a way that
mimics tRNA anticodon recognition. This leads to competition
between ThrRS and the 30S ribosomal subunit [40]. Interest-
ingly, the two essential regulatory events are controlled by dif-
Figure 4. Depiction of the genetic code. On the left. codons are colored according to the class of the synthetase that charges the corresponding
tRNA (class I in light gray, class II in dark gray) For simplicity, the lysine codon is colored as class II. On the right, codons are colored according to the
ARS pairs that link specific ARS subclasses (Ia–IIa in dark gray, Ib–IIb in light gray, Ic–IIc in white). A clear distribution of codons in three clusters can
be seen in the right panel. Stop codons are shown in black.
Figure 5. The binding of Escherichia coli ThrRS to the leader region of
its own mRNA. The four structural domains of the mRNA control region
are labeled D1–D4. The two structural domains of ThrRS are shown as
gray balls. RBS ribosome-binding site; the AUG codon is labeled and
shown as a solid box.
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ferent domains of the protein. Operon recognition involves the
catalytic and C-terminal domains of the synthetase, and ribo-
some competition is achieved by the N-terminal domain of
ThrRS (Fig. 5).
tRNAThr also participates directly in this mechanism by being
an efficient competitor of the mRNA operator region [41]. Thus,
tRNAThr and the operator compete for ThrRS binding, and the
ribosome and the enzyme compete for mRNA binding. When
the growth rate increases, the cellular concentrations of tR-
NAThr and 30S increase, causing ThrRS to mainly recognize tR-
NAThr and, as a result, full translation of thrS. By contrast, when
the concentrations of tRNAThr or 30S decrease, ThrRS binds to
its own mRNA, causing repression of expression and mRNA
degradation.
Regulation of expression of Saccharomyces cerevisiae as-
partyl-tRNA synthetase (AspRS) was the first example of a eu-
karyotic ARS regulated via a feedback mechanism similar to
the one described above. Frugier and co-workers demonstrat-
ed that yeast AspRS binds tightly and specifically to its own
mRNA both in vitro and in vivo [42]. Expression of AspRS is
regulated by a mechanism that necessitates recognition of the
5’ extremity of AspRS mRNA by its translation product, and
depends on the cellular tRNAAsp concentration. This regulation
leads to synchronized expression of AspRS and tRNAAsp [43,
44].
ARSs are also implicated in the quality control of protein
synthesis. Ribosomes can stall on an mRNA if the message
has no stop codon or if there is no cognate tRNA available for a
particular codon [45]. To rescue stalled ribosomes and elimi-
nate partially completed polypeptides from the cell, bacteria
use a quality-control mechanism mediated by an RNA known
as tmRNA, which is aminoacylated with alanine by alanyl-tRNA
synthetase (AlaRS).
TmRNA has the unique capacity to act as both a tRNA and
mRNA. Its cellular function is to release stalled ribosomes and
to induce the C-terminal tagging of prematurely truncated pro-
teins with a protease targeting sequence [45, 46].
Cell regulation functions of ARSs
In eukaryotic cells, the existence of a link between protein syn-
thesis and signal transduction was first suggested by the ob-
servation that cells treated with interferon (IFN)-γ strongly over-
expressed tryptophanyl-tRNA synthetase (TrpRS) [47, 48]. A
direct relationship between the two processes was later
demonstrated in human cells by Wakasugi and co-workers,
who showed that a human tyrosyl-tRNA synthetase (TyrRS)
has cytokine functions in addition to its role in protein synthesis
[49]. The intracellular form of this enzyme contains an N-termi-
nal catalytic domain and a C-terminal structure, which is ho-
mologous to human endothelial monocyte-activating polypep-
tide II (EMAPII).
Under apoptotic conditions in culture, full-length TyrRS is
secreted from cells and digested by leukocyte elastase (an ex-
tracellular protease) producing two distinct cytokines: one
formed by the active site domain of the enzyme (mini-TyrRS),
and a second one that corresponds to the EMAPII-like domain
of the native TyrRS [49].
The NH2-terminal catalytic domain of TyrRS contains a con-
served Glu-Leu-Arg (ELR) motif within its sequence that is
identical to that found in CXC chemokines, such as the angio-
genic factors interleukin-8, Gro-α, Gro-β, and Gro-γ. Indeed,
mini-TyrRS induces angiogenesis and functions as a chemoat-
tractant for polymorphonuclear leukocytes (PMNs) [49]. The
extra COOH domain of human TyrRS has cytokine activities
like those of mature human endothelial monocyte-activating
polypeptide II, and becomes an immune-cell stimulant for mi-
gration and production of tumor necrosis factor (TNF), tissue
factor, and myeloperoxidase.
A second form of cellular signaling function was later discov-
ered for tryptophanyl-tRNA synthetase (TrpRS), an enzyme re-
lated in structure to TyrRS. In human cells TrpRS exists in two
forms, the major form corresponds to the full-length protein,
and a truncated form (mini-TrpRS) results from alternative
splicing and lacks most of the NH2-terminal extension. Al-
though both human full-length TrpRS and mini-TrpRS are en-
zymatically active in aminoacylation, only the shorter form is ac-
tive as an inhibitor of vascular endothelial growth factor
(VEGF)-induced angiogenesis [50], thus displaying angiostatic
activity. As mentioned before, production of this NH2-terminally
truncated variant is stimulated in vitro by IFN-γ in a variety of
cells [51].
Recently, Tzima and co-workers reported that a truncated
TrpRS binds at intercellular junctions of endothelial cells. Using
genetic knock-outs, binding was established to depend on
vascular endothelial (VE)-cadherin, a calcium-dependent adhe-
sion molecule that is essential for normal vascular develop-
ment. Binding of the truncated TrpRS inhibited activation of
vascular endothelial growth factor (VEGF)-induced extracellular
receptor kinase (ERK) activation and cell migration [52].
ARS multi-synthetase complex
In eukaryotic cells, ARSs display a higher level of organization
in the form of multi-ARS complexes. At least nine different en-
zymes, glutamyl-tRNA synthetase (GluRS), prolyl-tRNA syn-
thetase (ProRS), isoleucyl-tRNA synthetase (IleRS), leucyl-
tRNA synthetase (LeuRS), methionyl-tRNA synthetase
(MetRS), glutaminyl-tRNA synthetase (GlnRS), arginyl-tRNA
synthetase (ArgRS), lysyl-tRNA synthetase (LysRS), and as-
partyl-tRNA synthetase (AspRS), have been identified in the
mammalian forms of these complexes [53, 54]. In addition,
these complexes also contain non-enzymatic factors, known
as p43, p38, and p18 (Fig. 6). tRNA channeling has been sug-
gested as a possible function for these mammalian multi-ARS
complexes, as an efficient way to control substrate distribution
during sequential reactions [55].
Many of the ARSs that form the multi-ARS complex also
have non-canonical functions. In the case of LysRS, it has
been shown that this enzyme is involved in the regulation of mi-
crophthalmia transcription factor (MITF) transcriptional activity
[56]. MIFT is a basic helix-loop-helix leucine zipper DNA-bind-
ing protein and its activity is inhibited by its interactions with a
tumor-suppressor protein, Hint. In quiescent leukemia cells,
LysRS forms a trimeric complex with MITF and Hint but, upon
immunologic activation, LysRS-synthesized Ap4A binds to
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Hint, liberating MITF. Once released, MITF activates target
genes, leading to the activation of mast cells. Interestingly,
LysRS has also been shown to be secreted from several cell
lines in response to TNF-α [57].
A second example of non-canonical regulatory function
comes from human MetRS, which constitutes one of the un-
common cases of nuclear localization of ARSs [58]. MetRS is
translocated to the nucleus under proliferative conditions to
augment rRNA synthesis in nucleoli. The presence of MetRS in
the nucleoli depends on the integrity of rRNA and the activity of
RNA polymerase, suggesting that MetRS plays a role in rRNA
synthesis [58] and act as a sensor protein coupling translation
and rRNA biosynthesis [59].
Human GlnRS has also been implicated in the control of cell
proliferation and in the regulation of cell death through an an-
tagonistic interaction with ASK1, a protein kinase that has a
critical role in apoptosis [60]. The interaction of the two proteins
is stimulated by glutamine, which can suppress cell death [60].
Like ARSs, ARS-associated factors in the multi-ARS com-
plex play diverse roles in processes other than protein synthesis.
p43 is secreted as an active cytokine [61-64], inducing the syn-
thesis of various pro-inflammatory cytokines and chemokines,
such as TNF-α, interleukin-8, monocyte chemotactic protein-1,
and interleukin-1β from monocytes [60], as well as intracellular
adhesion-molecule-1 [65]. Seemingly, p43 also plays a complex
role in angiogenesis. Although it induces migration of endothelial
cells at low concentrations, at high concentrations it can sup-
press vascular growth by blocking the proliferation and trigger-
ing apoptosis of endothelial cells [65].
The sequence of p43 contains a caspase-cleavage site,
which releases the C-terminal domain of p43 from the multi-
ARS complex. This process was thought to trigger the secre-
tion of the cytokine component from p43, causing the disinte-
gration of the multi-ARS complex to block protein synthesis
[66]. However, p43 processing does not appear to affect the
function of the complex, and it turns out that the uncleaved
form of p43 is the active cytokine [64]. The role of proteolytic
cleavage of p43 in apoptosis is thus unclear at this point.
Another component of the multi-ARS complex, p38, also
has an unexpected additional role. This protein can bind to
FUSE-binding protein (FBP), a transcriptional activator of the
myc gene, promoting its ubiquitylation and proteasome-de-
pendent degradation [67]. When the expression of endoge-
nous p38 is abolished, myc is overexpressed owing to the lack
of p38-mediated suppression, which causes hyperproliferation
of lung cells. The consequent malfunction of the lung causes
p38–/– mice to die at birth, although they survive development
through the prenatal stage [67].
It is not known yet whether the smallest cofactor, p18, is
also multi-functional. It shares limited sequence similarity with
elongation-factor subunits [68]. Park and colleagues reported
that p18 directly interacts with serine/threonine kinases to acti-
vate p53, and works as a potent tumor suppressor [69].
Aminoacyl tRNA synthetase-like proteins
Large-scale sequencing efforts have revealed that many
genomes contain ARS-like proteins that are evolutionarily relat-
ed to functional domains from canonical ARSs [70]. The func-
tions of these proteins, however, are largely unknown, and
possibly completely unrelated to those of their homologous
ARSs.
A subset of these ARS-like proteins is associated with the
synthesis of amino acids and cofactors. Sissler et al. described
a class of ARS-like proteins (HisZ) in Lactococcus lactis that
are homologous to the catalytic domain of histidyl-tRNA syn-
thetase (HisRS). These proteins lack aminoacylation activity,
but are instead essential components of the first enzyme in the
pathway for histidine biosynthesis: ATP phosphoribosyltrans-
ferase (His G) [71].
The observation of a protein linking amino acid synthesis
and protein synthesis implies an early connection between the
biosynthesis of amino acids and proteins [70]. Indeed, genetic
studies in yeast have identified a protein kinase, GCN2, that
acts as a primary sensor of amino acid starvation [72]. This
protein displays four functional domains: an N-terminal domain
that binds other activators, a protein kinase domain, a domain
highly homologous to HisRS, and a C-terminal domain confer-
ring binding properties to GNC2. Amino acid starvation causes
the accumulation of uncharged tRNAs that bind to the HisRS-
related domain of GNC2 and activate the adjacent protein ki-
nase, which, in turn, phosphorylates the translation factor
eIF2α, inhibiting protein synthesis [73]. The biological meaning
of this reaction remains unclear.
Some ARS-like proteins are involved in RNA modification.
Such is the case of YadB, a recently described GluRS-like pro-
tein that chemically modifies tRNA [74]. YadB has the ability to
Figure 6. Model of the organization of the mammalian tRNA syn-
thetase complex. Nine different ARSs, including class I and class II en-
zymes, have been consistently found in mammalian systems. Non-en-
zymatic factors are labeled p18, p38, and p43.
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activate glutamate [75], although without the need for tRNA
binding that characterizes GluRS [76]. YadB does not attach
activated glutamate to tRNAGln or tRNAGlu but instead to the
anticodon region of tRNAAsp [77]. Salazar et al. have shown
that, rather than transferring glutamate to the 3′ end of the
tRNA as GluRS would do, YadB attaches glutamate to the hy-
permodified nucleoside queuosine at the first anticodon posi-
tion of tRNAAsp, leading to the formation of glutamyl-queuosine
[74]. The biological meaning of this reaction is also unclear.
Other ARS-like proteins are involved in the control of transla-
tional fidelity. For instance, a homologue of a ProRS domain,
the PrdX protein from Clostridium sticklandii, efficiently and
specifically hydrolyzes Ala-tRNAPro [78], thus preventing the
misincorporation of alanine instead of proline into proteins by
misacylated tRNAPro. Similarly, autonomous AlaRS domain ho-
mologues (AlaX proteins) from Methanosarcina barkeri and
Sulfolobus solfataricus hydrolyze Ser-tRNAAla and Gly-tRNAAla
substrates [78]. Finally, YbaK, a protein from Haemophilus in-
fluenzae with high sequence identity to the prokaryotic ProRS
editing domain, has been shown to be capable of deacylating
Ala-tRNAPro [79].
Finally, a few other ARS-like proteins are involved in cellular
transport processes. For instance, MetRS-like proteins, such
as Trbp111 in Aquifex aeolicus [80] and Arc1P in Saccha-
romyces cerevisiae (homologues of mammalian p43 discussed
above), have been shown to bind to tRNA [81, 82] and are in-
volved in the nuclear transport of tRNA. In addition, Arc1P
forms a complex with MetRS and GluRS [83], and could act as
an organizer of tRNA synthetases in yeast [55].
Aminoacyl-tRNA synthetases in human disease
Ever since initial reports in the 1980s that linked ARSs to hu-
man autoimmune diseases [84], the links between ARSs and
health disorders have grown steadily. So far, these connec-
tions appear to be mainly related to the canonical aminoacyla-
tion function of ARSs, but suggestions of pathological effects
related to the non-canonical functions discussed above are
starting to emerge.
The better-characterized pathologies related to tRNA and
ARS are muscular disorders caused by deficiencies in mito-
chondrial tRNA aminoacylation. Aminoacylation of mitochondr-
ial tRNAs is carried out by ARSs encoded in the nuclear
genome. Some of these enzymes are specific for this or-
ganelle, while others function also in the cytoplasm. Incorrect
translation of the mitochondrial genome causes severe deple-
tion of the respiratory pathways and results in several disorders
that often affect muscular tissue.
Mutations affecting the mitochondrial translation apparatus
generate diseases such as mitochondrial myopathy, Leigh syn-
drome, Leber’s hereditary optic neuropathy, chronic progressive
external ophthalmoplegia, Kearns Sayre syndrome, maternal
myopathy and cardiomyopathy, progressive encephalopathy,
diabetes mellitus, and deafness. More than 100 mutations in-
volving rRNA and tRNA have been found in mtDNA (see
http://www.mitomap.org).
Mitochondrial encephalopathy with lactic acidosis and
stroke-like episodes (MELAS) is a clear example of a disease
caused by mutations in mitochondrial tRNAs that decrease
their aminoacylation efficiency. Several tRNA mutations are
linked to the MELAS phenotype, most of them affecting the mi-
tochondrial tRNALeu (UUR). The most frequent are A3243G
[85], A3252G [86], G3244A, T3291C [87], C3256T [88], and
T3271C [89]. Some of these mutations decrease leucylation
efficiency compared to wild-type tRNALeu due to folding alter-
ations of the tRNA molecule (Fig. 7).
Myoclonic epilepsy with ragged red fibers (MERRF) is a sec-
ond example of mitochondrial disease related to tRNA muta-
tions. Symptoms of the disease include myoclonus, variable
seizures, ataxia, dementia, corticospinal tract degeneration,
peripheral neuropathy, optic atrophy, deafness, central hy-
poventilation syndrome with respiratory failure, and myoclonic
epilepsy [90]. Several mitochondrial tRNALys mutations have
been reported to be the cause of MERRF; for example:
A8344G [91, 92], G8361A [93], T8356C [94], and G8361
(which includes other phenotypes like Leigh’s syndrome, my-
oclonus or myopathy with truncal lipomas, and proximal my-
opathy). The A8344G mutation causes a decrease in tRNALys
aminoacylation by lysyl-tRNA synthetase, and the lack of
aminoacylated tRNALys might be the cause of premature termi-
nation of translation close to lysine codons [95].
Thus, most mitochondrial diseases linked to tRNA aminoa-
cylation seem to be caused by changes in the tRNA structure.
However, mutations in genes coding for ARSs have also been
linked to human disorders. For instance, it has been reported
that a mutation in the human mitochondrial leucyl-tRNA syn-
thetase gene may represent a novel type-2 diabetes suscepti-
bility gene [96].
In addition, mutations in glycyl-tRNA synthetase (GlyRS)
have been found in Charcot-Marie-Tooth (CMT) disease pa-
tients. CMT is the most commonly inherited neurological disor-
der, found world-wide in all races and ethnic groups. Type 2D
CMT could be caused by two mutations in the GlyRS gene:
Gly-240→Arg or Glu-71→Gly [97]. Similarly, distal spinal mus-
cular atrophy type V is also associated with mutations in GlyRS
(Leu-129→Pro, Gly-526→Arg) [97].
Finally, a connection between certain tryptophanyl-tRNA
synthetase polymorphisms and the pathophysiology of vascu-
lar angiogenesis and homeostasis has been proposed, al-
though, as yet, there is no evidence for a direct link between
these polymorphisms and susceptibility to myocardial infarc-
tion [98].
Synthetases also act as antigens in human inflammatory
myopathies [99]. Antibodies directed against histidyl-tRNA
synthetase (anti-Jo-1) are the most commonly produced by
patients with polymyositis, a disease characterized by weak-
ness and wasting of muscle. Anti-Jo-1 also causes interstitial
lung disease (ILD) and arthritis [84].
Other anti-ARS autoantibodies have also been found in pa-
tients with polymyositis and interstitial lung disease: anti-PL-12
antibodies are directed at AlaRS and cause similar symptoms
as anti-Jo-1 myositis [100]. Anti-PL-7 autoantibodies react
against ThrRS and constitute an uncommon myositis-associ-
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ated antibody type [101] that also causes pulmonary fibrosis
and dermatomyositis with erosive arthropathy [102]. Anti-EJ
antibodies directed against GlyRS are associated with myositis
and interstitial lung disease [103]. Anti-OJ antibodies react
against IleRS and are responsible for myositis and severe inter-
stitial lung disease. Anti-OJ antibodies are the only anti-ARS
antibodies that are directed against a member of the multi-
enzyme complex [104]. Anti-KS are autoantibodies against
AsnRS that are present in patients with interstitial lung disease
and inflammatory arthritis, but without evidence of myositis
[105].
Aminoacyl-tRNA synthetases as anti-infective
targets
ARSs represent ideal targets for antibiotic development be-
cause they are essential enzymes of universal distribution
whose ancestral nature allows for the selection of specific in-
hibitors [106]. In addition, they are soluble, stable, easy to ex-
press and purify in large amounts, and are straightforward to
assay by one or more methods. X-ray structures are available
for all synthetases, and much is known about the mechanism
of the aminoacylation reaction.
Although there are several natural inhibitors directed against
aminoacyl-tRNA synthetases, i.e. borrelidin (ThrRS), fura-
nomycin (IleRS), granaticin (LeuRS), indolmycin (TrpRS), ochra-
toxin A (PheRS), cispentacin (ProRS), etc., most suffer from
lack of inhibitory activity, poor specificity, or poor bioavailability.
As a result, only one of these molecules has so far been devel-
oped into a commercial antibiotic (Table 1).
Pseudomonic acid A (mupirocin, marketed as Bactroban) is
the best known natural inhibitor of a synthetase [107] (Fig. 8). It
is synthesized by Pseudomonas fluorescens, inhibits isoleucyl-
tRNA synthetase from several bacterial pathogens, and shows
about 8,000-fold selectivity for pathogenic IleRS over mam-
malian IleRS [108]. Unfortunately, its low systemic bioavailabili-
ty restricts its application to the treatment of topical infections.
In the search for better ARS inhibitors, several mupirocin ana-
logues showing broad anti-infective activities, including antifun-
Figure 7. Human mitochondrial tRNALeu (UUR) with reported provisional and confirmed mutations related to several diseases (see
www.mitomap.org), such as: CPEO chronic progressive external ophthalmoplegia, DM diabetes mellitus, DMDF diabetes mellitus and deafness,
KSS Kearns Sayre syndrome, LHON Leber hereditary optic neuropathy, MELAS mitochondrial encephalomyopathy, lactic acidosis, and stroke-like
episodes, MERRF myoclonic epilepsy and ragged red muscle fibers, MM mitochondrial myopathy, MMC maternal myopathy and cardiomyopathy,
PEM progressive encephalopathy.
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ARS Compound Organisms
Staphylococcus aureus (even resistant strains),
Methionyl-tRNA synthetase REP8839 [127, 128] S. epidermidis, S. pyogenes and other
Gram positive bacteria
Valyl-tRNA synthetase SB– 203207 analogues [129] bacteria
Leucyl-tRNA synthetase Agrocin 84 [130] Agrobacterium tumefaciens
SB– 203207 analogues [129] bacteria
Escherichia coli
Pseudomonic acid A [131-133]
S. aureus
Isoleucyl-tRNA synthetase Dermatophites,  Pityrosporum spp,
Trichophyton mentagrophytes and Candida albicans
icofungipen (PLD-118) [134, 135] C. albicans (also Fuconazole resistant strains)
Arginyl-tRNA synthetase
Sparteine sulfate [136] Lupinus spp.
Aminoalkyl adenylates [137] S. aureus
Glutamyl-tRNA synthetase
Glutamylsulfamoyladenosine and E. coli
Pyroglutamylsulfamoyladenosin [138]
Glutaminyl-tRNA synthetase
Glutaminol adenylate and Methyl E. coli
phosphate ester [139]
Tyrosyl-tRNA synthetase SB-219383 [140] [141] Staphylococcus spp.
Tryptophanyl-tRNA synthetase
Chuangxinmycin [142] Bacteria, E. coli and Shigella dysenteriae
Indolmycin [143] [144] E. coli and Staphylococcus spp.
Seryl-tRNA synthetase SB-217452[145] S. aureus and rat
Threonyl-tRNA synthetase Borrelidin [146] E. coli
Prolyl-tRNA synthetase Quinoline inhibitors [147] C. albicans
Aspartyl-tRNA synthetase nonhydrolyzable aspartyl adenylate analogs [148] E. coli
E. coli, H. influenzae, S. Pneumoniae, S.aureus,
Phenylalanyl-tRNA synthetase Phenyl-thiazolylurea-sulfonamides [149] Staphylococcus, Streptococcus,
Haemophilus and Moraxella strains.
Table 1. Examples of known ARS inhibitors.
Figure 8. Examples of two ARS inhibitors. agrocin 84 vs. leucyl adenylate (left), and pseudomonic acid A vs. isoleucyl adenylate (right).
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gal, antimycoplasmal, and herbicidal activities, have been re-
ported [109–117].
More recently, a set of methionyl-tRNA synthetase inhibitors
that are active against staphylococcal and enterococcal antibi-
otic-resistant strains have been described [118]. The same
group has developed ethanolamine inhibitors that block
phenylalanyl-tRNA synthetase from Staphylococcus aureus.
Some of the latter have a selectivity that is 5,000-fold higher
against bacterial enzymes than against mammalian PheRS
[119]. Thus, interest in ARSs continues to grow but a solid
pipeline of potential lead compounds is still lacking.
In addition to their potential application as compounds ac-
tive against cellular pathogens, recent reports on the role of
some aminoacyl-tRNA synthetases and their cognate tRNAs in
the packaging of retroviruses have awakened interest in the
possibility of targeting these proteins in anti-viral therapies. The
best known case of involvement of an ARS in viral packaging is
that of tRNALys and LysRS packaging into human immunodefi-
ciency virus type 1 (HIV-1); however, other retroviruses use
similar mechanisms. For example, Rous sarcoma virus uses
tRNATrp as primer for the reverse transcriptase (RT) [120], and
tRNAPro is used as primer for Moloney murine leukemia viruses
(MuLV) [121].
During HIV-1 virion packing, three human tRNALys isoaccep-
tors are associated with the viral genomic RNA. The tRNALys3
isoacceptor anneals near the 5′ end of the viral RNA genome to
an 18-nucleotide sequence (primer-binding site), where it is
used as primer by the viral reverse transcriptase for the tran-
scription of the viral genome into DNA [122]. The role of
tRNALys1, 2 isoacceptors that are also packed in the virion is still
unclear [122].
Incorporation of tRNALys into the virion also requires the
packaging of Gag-Pol protein and lysyl-tRNA synthetase.
While the interaction between tRNALys and LysRS is essential
for packaging [123], aminoacylation of tRNALys seems to be
dispensable [124]. In fact, the HIV-1 virion contains deacylated
tRNALys, whereas the host cell contains mostly acylated
tRNALys [123]. The presence of a deacylating system, which
might be necessary for the RT to extend the 3′ adenosine
tRNALys3 , has been proposed [125].
Lysyl-tRNA synthetase plays a second role in the packaging
of HIV-1. During early assembly of HIV-1, an assembly complex
is formed by genomic RNA, Gag, GagPol, tRNALys, and LysRS.
Changes in cellular expression of LysRS result in corresponding
changes in viral infectivity and in the amounts of LysRS, tR-
NALys, and viral RT packed in the virions [126]. It has been pro-
posed that the altered viral contents of RT resulting from alter-
ations in cellular LysRS concentrations result from the ability of
LysRS to inhibit premature activation of Gag-Pol viral protease
within the complex. Increases and decreases in cellular LysRS
expression are accompanied by five- to eight-fold increases
and five-fold decreases, respectively, in the cytoplasmic prote-
olysis of Gag and GagPol. Accordingly, overexpression of
LysRS in the cell reduces viral protease activity [126]. All these
considerations suggest that specific ARS inhibitors may, in the
future, find additional indications in the treatment of retroviral in-
fections.
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